Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
Amitay-Laish
Iris
I
David
Michael
M
Hodak
Emmilia
E
D000077610:Bexarotene; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D019233:Retreatment; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D013764:Tetrahydronaphthalenes; D000077610:Bexarotene